# OnCo record idea-tr1-adaptive-therapy-randomised-phase-2 (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-tr1-adaptive-therapy-randomised-phase-2/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-tr1-adaptive-therapy-randomised-phase-2" ;
  schema:name "Evolution-guided 'adaptive therapy' dosing tested in randomised phase 2 trials"@en ;
  schema:description "Adaptive therapy uses just enough drug to keep a tumour in check, pausing when the burden falls and resuming when it rises, so drug-sensitive cells suppress resistant ones. A prostate cancer pilot with abiraterone lengthened time to progression against historical controls on half the drug; randomised phase 2 trials are the next step."@en ;
  schema:url <https://onco.cc/ideas/idea-tr1-adaptive-therapy-randomised-phase-2/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://www.nature.com/articles/s41467-017-01968-5> ;
  onco:related <https://onco.cc/roadmaps/prostate-roadmap/>, <https://onco.cc/ideas/idea-prostate-bipolar-androgen-therapy-phase-3-on-pfs2/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/ovarian/> ;
  onco:institutions <https://onco.cc/institutions/moffitt/> ;
  onco:terms <https://onco.cc/terms/resistance/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-dose-optimisation/>, <https://onco.cc/bottlenecks/b-resistance/> .